Short answer
Denali Therapeutics Inc. (DNLI) filed an 8-K current report with the SEC on February 26, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q4 2025 earnings press release issued Feb 26, 2026: full financial results in Exhibit 99.1.
Denali Therapeutics Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q4 2025 earnings press release issued Feb 26, 2026: full financial results in Exhibit 99.1
- Key figures (revenue, cash, pipeline metrics) not disclosed in filing body: refer to attached press release for details
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Denali Therapeutics Inc. 8-K filings
Get the next DNLI 8-K as it lands
Follow DNLI for push alerts, or ask the research agent what this filing means.